In conclusion, we found that H3K9 acetylation in the Egr-1 binding sites of GDNF promoter II, binding of Egr-1 to such sites, RNA POL II recruitment in that region, and Egr-1 expression were significantly increased in high-grade glioma tissue. The gene discussed is GDNF; the disease is central nervous system cancer.